Formulary Group work programme


Forthcoming submissions 2014

This list is indicative and may be subject to change.

Alogliptin - SMC 937/14 - Formulary Group advice will be published by 4th November 2014. (Indication: for adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control).

Alogliptin plus metformin (Vipdomet®) - SMC 998/14 - Formulary Group advice will be published by 4th November 2014. (Indication: the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus).

Atomoxetine - SMC 909/13 - in progress. (Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme).

Azelastine/fluticasone nasal spray (Dymista®) - SMC 921/13 - Formulary Group advice will be published by 4th November 2014. (Indication: for the relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient).

Brentuximab - SMC 989/14 - Formulary Group advice will be published by 4th November 2014. (Indication: treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL)).

Capsaicin - SMC 673/11 - Formulary Group advice will be published by 4th November 2014. (Indication: for the treatment of peripheral neuropathic pain in non-diabetic adults either alone or in combination with other medicinal products for pain).

Dabigatran - SMC 995/14 - Formulary Group advice will be published by 4th November 2014. (Indication: treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults).

Eltrombopag - SMC 919/13 - in progress. (Indication: in adult patients with chronic hepatitis C virus infection, for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy).

Empagliflozin - SMC 993/14 - Formulary Group advice will be published by 4th November 2014. (Indication: treatment of type 2 diabetes to improve glycaemic control in adults as add-on combination therapy).

Enoximone - FG1 361/14 - Formulary Group advice will be published by 4th November 2014. (Indication: post cardiac surgery).

Fingolimod - SMC 992/14 - Formulary Group advice will be published by 4th November 2014. (Indication: as a single disease modifying therapy in highly active relapsing remitting multiple sclerosis).

Lurasidone - SMC 994/14 - Formulary Group advice will be published by 4th November 2014. (Indication: for the treatment of schizophrenia in adults aged 18 years and over).

Misoprostol - SMC 996/14 - in progress - (Indication: induction of labour in women with an unfavourable cervix, from 36 weeks gestation, in whom induction is clinically indicated).

Nalmefene - SMC 917/13 - in progress. (Indication: for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms, and who do not require immediate detoxification).

Nepafenac - SMC 813/12 - in progress. (Indication: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients).

Ondanestron - SMC 912/13 - in progress. (Indication: in adults: Prophylaxis and treatment of acute and delayed nausea and vomiting induced by chemotherapy, and radiotherapy. Prophylaxis and treatment of post-operative nausea and vomiting.
In paediatric populations:Management of chemotherapy-induced nausea and vomiting in children aged ≥6 months and prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years).

Ocriplasmin - SMC 892/13 - in progress. (Indication: in adults for the treatment of vitreomacular traction).

Posaconazole - SMC 995/14 - Formulary Group advice will be published by 4th November 2014. (Indication: the treatment of fungal infections in adults).

Rituximab subcutaneous injection - SMC 975/14 - in progress. (Indication: for non-Hodgkin's lymphoma (NHL) in adults).

Simeprevir - SMC 988/14 - Formulary Group advice will be published by 4th November 2014. (Indication: in combination with other medicinal products for the treatment of chronic hepatitis C in adult patients).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

« Previous: Formulary Group | Top | Next: Formulary Group decisions index »